Analyst Coverage
Stock price graph

We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Repros Therapeutics Inc.'s financial performance into perspective.

Recent Releases

Apr 17, 2017
Repros Announces the Issuance of New U.S. Patent Relating to Treatment Using Off Drug Intervals For Certain Uterine Conditions

Apr 10, 2017
Repros Names Larry Dillaha, M.D., its Permanent President and CEO

View all releases »

2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3446 fax